New therapies – AIMSPRO
The Food and Drug Administration has at the end of February 2014 granted Orphan Drug designation to the therapy AIMSPRO, for systemic sclerosis. Widely known by the acronym FDA, the organisation has a wide-ranging effect on decisions made regarding drugs elsewhere in the world.
A double-blind, placebo-controlled Phase II clinical study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic Sclerosis (dSSc) is now wholly complete. The encouraging results from this study were published in Annals of Rheumatic Diseases.
The detailed announcement of the Orphan Drug designation is on Daval’s website :
news & events